0001213900-22-024238 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2022	May 02, 2022
Document Information Line Items
Entity Registrant Name	Protara Therapeutics, Inc.
Trading Symbol	TARA
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		11,251,927
Amendment Flag	false
Entity Central Index Key	0001359931
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36694
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-4580525
Entity Address, Address Line One	345 Park Avenue South
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	(646)
Local Phone Number	844-0337
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 25,436	$ 35,724
Marketable debt securities	62,155	55,505
Prepaid expenses and other current assets	3,098	1,883
Total current assets	90,689	93,112
Restricted cash, non-current	745	745
Marketable debt securities, non-current	30,889	39,467
Property and equipment, net	1,676	1,719
Operating lease right-of-use asset	6,953	7,171
Goodwill	29,517	29,517
Other assets	787	865
Total assets	161,256	172,596
Current liabilities:
Accounts payable	541	954
Accrued expenses	1,450	2,489
Operating lease liability	870	855
Total current liabilities	2,861	4,298
Operating lease liability, non-current	6,160	6,384
Total liabilities	9,021	10,682
Commitments and contingencies (Note 8)
Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 shares authorized at March 31, 2022 and December 31, 2021, 8,027 shares issued and outstanding as of March 31, 2022 and December 31, 2021.
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,251,927 and 11,235,731 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively.	11	11
Additional paid-in capital	257,933	256,126
Accumulated deficit	(104,767)	(94,012)
Accumulated other comprehensive income (loss)	(942)	(211)
Total stockholders’ equity	152,235	161,914
Total liabilities and stockholders’ equity	$ 161,256	$ 172,596

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,251,927	11,235,731
Common stock, shares outstanding	11,251,927	11,235,731
Series 1 Convertible Preferred Stock
Preferred stock, shares authorized	8,028	8,028
Preferred stock, shares issued	8,027	8,027
Preferred stock, shares outstanding	8,027	8,027

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 5,269	$ 7,040
General and administrative	5,605	6,540
Total operating expenses	10,874	13,580
Loss from operations	(10,874)	(13,580)
Other income (expense), net:
Interest and investment income	119	115
Other income (expense), net	119	115
Net loss	$ (10,755)	$ (13,465)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.96)	$ (1.2)
Weighted-average shares outstanding, basic and diluted (in Shares)	11,250,127	11,226,929
Other comprehensive income (loss):
Net unrealized (loss) gain on marketable debt securities	$ (731)	$ (164)
Other comprehensive income (loss)	(731)	(164)
Comprehensive Loss	$ (11,486)	$ (13,629)

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance of beginning at Dec. 31, 2020		$ 11	$ 245,992	$ (46,760)		$ 199,243
Balance of beginning (in Shares) at Dec. 31, 2020	8,027	11,211,840
Settlement of restricted stock units			(228)			(228)
Settlement of restricted stock units (in Shares)		16,766
Stock-based compensation - restricted stock units			1,303			1,303
Stock-based compensation - stock options			1,437			1,437
Unrealized (loss) gain on marketable debt securities					(164)	(164)
Net loss				(13,465)		(13,465)
Balance of Ending at Mar. 31, 2021		$ 11	248,504	(60,225)	(164)	188,126
Balance of Ending (in Shares) at Mar. 31, 2021	8,027	11,228,606
Balance of beginning at Dec. 31, 2021		$ 11	256,126	(94,012)	(211)	161,914
Balance of beginning (in Shares) at Dec. 31, 2021	8,027	11,235,731
Settlement of restricted stock units			(72)			(72)
Settlement of restricted stock units (in Shares)		16,196
Stock-based compensation - restricted stock units			314			314
Stock-based compensation - stock options			1,565			1,565
Unrealized (loss) gain on marketable debt securities					(731)	(731)
Net loss				(10,755)		(10,755)
Balance of Ending at Mar. 31, 2022		$ 11	$ 257,933	$ (104,767)	$ (942)	$ 152,235
Balance of Ending (in Shares) at Mar. 31, 2022	8,027	11,251,927

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows used in operating activities:
Net loss	$ (10,755)	$ (13,465)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,879	2,740
Operating lease right-of-use asset	341	55
Depreciation	56	32
Amortization of premium on marketable debt securities	410	283
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,186)	(1,971)
Other assets	78	65
Accounts payable	(413)	938
Accrued expenses	(1,039)	(545)
Operating lease liabilities	(332)	(52)
Net cash used in operating activities	(10,961)	(11,920)
Cash flows from investing activities:
Purchase of marketable debt securities	(12,415)	(97,959)
Proceeds from maturity and redemption of marketable debt securities	13,171
Purchase of property and equipment	(11)	(290)
Net cash provided by/(used in) investing activities	745	(98,249)
Cash flows from financing activities:
Repurchase of shares in connection with settlement of RSUs	(72)	(228)
Net cash used in financing activities	(72)	(228)
Net decrease in cash and cash equivalents and restricted cash	(10,288)	(110,397)
Cash and cash equivalents and restricted cash - beginning of year	36,469	169,393
Cash and cash equivalents and restricted cash - end of period	26,181	58,996
Reconciliation of cash and cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents	25,436	58,201
Restricted cash		50
Restricted cash, non-current	745	745
Cash and cash equivalents and restricted cash	$ 26,181	$ 58,996

Organization and Nature of the Business

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Organization and Nature of the Business

1.	Organization and Nature of the Business

Overview

Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company committed to identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations, or LMs and non-muscle invasive bladder cancer, or NMIBC. The third program in the portfolio is Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition, or PN who have intestinal failure associated liver disease, or IFALD.

Liquidity, Capital Resources and Management Plans

The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.

The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.

Impact of the COVID-19 Pandemic

The ultimate impact of the current COVID-19 pandemic is highly uncertain and subject to change. The Company has experienced delays and may experience additional future delays that impact the business, research and development activities, the healthcare systems in which the Company operates and the global economy as a whole. Due to the continued evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the ongoing effects on the Company’s results of operations, financial condition, or liquidity. The Company will continue to monitor the COVID-19 public health crisis closely including whether the effects would have a material impact on the Company’s operations, liquidity and capital resources.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the United States Securities and Exchange Commission, or SEC, on March 9, 2022. Except as reflected below, there were no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K. Reflected in this note are updates to accounting policies, including the impact of the adoption of new policies.

Basis of Presentation

The accompanying condensed consolidated financial statements and the related disclosures as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2021 and 2020 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2021 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three months ended March 31, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Significant items subject to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and contingencies.

On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.

Concentrations of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash, cash equivalents and investments in marketable debt securities.

The Company currently invests its excess cash primarily in money market funds and high quality investment grade marketable debt securities of corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market.

Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:

	●	Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

	●	Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

	●	Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

The following tables present the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques it utilizes to determine such fair value:

	March 31, 2022
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	14,718	$	-	$	-	$	14,718
Restricted cash, non-current:
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		93,044		-		93,044
Total	$	15,463	$	93,044	$	-	$	108,507

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	26,323	$	-	$	-	$	26,323
Restricted cash, non-current:
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		94,972		-		94,972
Total	$	27,068	$	94,972	$	-	$	122,040

Money market funds are classified as Level 1 within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified as Level 2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices and market transactions in comparable investments and various relationships between investments. There were no transfers of financial instruments among Level 1, Level 2, and Level 3 during the period presented.

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at Mach 31, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Debt Securities

3 Months Ended

Mar. 31, 2022

Marketable Debt Securities [Abstract]

Marketable Debt Securities

4.	Marketable Debt Securities

Marketable debt securities, all of which were classified as available-for-sale, consist of the following:

	March 31, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate bonds - presented in marketable debt securities	$	62,535	$	-	$	(380	)	$	62,155
Corporate bonds - presented in marketable debt securities, non-current		31,451		-		(562	)		30,889
Total	$	93,986	$	-	$	(942	)	$	93,044

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate Bonds - presented in marketable debt securities	$	55,548	$	-	$	(43	)	$	55,505
Corporate Bonds - presented in marketable debt securities, non-current		39,635		-		(168	)		39,467
Total	$	95,183	$	-	$	(211	)	$	94,972

The Company has recorded the securities at fair value in its condensed consolidated balance sheets and unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The amount of realized gains and losses reclassified into earnings are based on the specific identification of the securities sold or securities that reached maturity date. The amount of realized gains and losses reclassified into earnings have not been material to the Company’s condensed consolidated statements of operations.

At the time of purchase, the Company determines the appropriate classification of investments based upon its intent with regard to such investments. The Company classifies investments in marketable debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining maturity date greater than one year are classified as non-current. The contractual maturities of all securities held at March 31, 2022 was 21 months or less. There were no sales of securities in the periods presented.

Of the 42 securities in a loss position held by the Company, there were five securities in a continuous unrealized loss position for greater than twelve months at March 31, 2022. The total unrealized loss related to these securities was $133 and was not material. The Company has the ability to hold such securities with an unrealized loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of the above investments. No other than temporary impairment loss has been recorded on the securities as of March 31, 2022, as the Company believes that any decrease in fair value of these securities is temporary and the Company expects to recover at least up to the initial cost of the investment for these securities.

Investment Income

Investment income consists of the following:

	March 31,
	2022			2021
Interest income	$	529		$	397
Accretion/(amortization) of discount/premium, net		(410	)		(282	)
Total interest and investment income	$	119		$	115

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2022

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

Included in the Company’s prepaid expenses and other current assets within the condensed consolidated balance sheets are:

	As of
	March 31, 2022		December 31, 2021
Prepaid insurance	$	1,683	$	279
Prepaid research and development		463		684
Prepaid software		133		79
Accrued interest on marketable debt securities		528		634
Other prepaid expenses		287		173
Other current assets		4		34
Total	$	3,098	$	1,883

Accrued Expenses

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

Accrued Expenses

6.	Accrued Expenses

Included in the Company’s accrued expenses within the condensed consolidated balance sheets are:

	As of
	March 31, 2022		December 31, 2021
Payroll	$	465	$	1,801
Taxes		52		41
Legal fees		56		29
Research and development costs		798		437
Other expenses		79		181
Total	$	1,450	$	2,489

Leases

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Leases

7.	Leases

Operating leases

Leases classified as operating leases are included in operating lease right-of use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company’s consolidated balance sheets. Cash paid for operating lease liabilities was $332 and $52 during the three months ended March 31, 2022 and 2021, respectively, which is included in operating cash flows.

The components of lease expense were as follows:

	Three Months Ended March 31,
Lease cost	2022		2021
Operating lease cost	$	341	$	55
Short-term lease cost		3		61
Total	$	344	$	116

Variable lease expense for the three months ended March 31, 2022 and 2021, respectively, was not material.

The weighted-average remaining lease term and the weighted average discount rate for operating leases were:

	As of March 31, 2022

Weighted-average discount rate		7.0	%
Weighted-average remaining lease term – operating lease (in months)		76

As of March 31, 2022, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows:

For Years Ending December 31,	Operating Lease Payments
2022 (excluding the three months ended March 31, 2022)	$	995
2023		1,327
2024		1,327
2025		1,395
2026		1,429
Thereafter		2,234
Total operating lease payments		8,707
Less: imputed interest		1,677
Present value of future minimum lease payments	$	7,030

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	Commitments and Contingencies

Commitments

The Company has commitments under certain license and collaboration agreements, lease agreements, and employment agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed products. Commitments under lease agreements consist of future minimum lease payments for operating leases which are further described in Note 7 of this Quarterly Report on Form 10-Q.

Contingencies

From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.

In the normal course of business, the Company enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties in which the Company believes the outcome could result in losses or penalties in the future.

Stockholders’ Equity

3 Months Ended

Mar. 31, 2022

Stockholders' Equity Note [Abstract]

Stockholders’ Equity

9.	Stockholders’ Equity

Common Stock

As of March 31, 2022 and December 31, 2021, the Company has 100,000,000 shares of common stock authorized for issuance, $0.001 par value per share, of which 11,251,927 and 11,235,731 shares were issued and outstanding, respectively.

The holders of the Company’s common stock are entitled to one vote per share.

Preferred Stock

As of March 31, 2022 and December 31, 2021, the Company has 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, of which 8,028 shares of Series 1 Convertible Preferred Stock are authorized for issuance and 8,027 shares were issued and outstanding. Each share of Series 1 Convertible Preferred Stock is convertible into approximately 1,000 shares of common stock, at a conversion price initially equal to approximately $7.01 per common share, subject to certain adjustments as described in the certificate of designation of preferences, rights and limitations of Series 1 Convertible Preferred Stock.

The holders of Series 1 Convertible Preferred Stock are not entitled to vote.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock-Based Compensation

3 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

10.	Stock-Based Compensation

2020 Inducement Plan

On March 26, 2020, the Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the 2020 Inducement Plan in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.

The 2020 Inducement Plan provides for a total of 600,000 shares for the issuance of the Company’s common stock. The Compensation Committee also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the Inducement Plan.

As of March 31, 2022, 438,834 shares remain available to be issued under the 2020 Inducement Plan.

2017 Equity Incentive Plan

On August 10, 2017, Private ArTara (a predecessor entity of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and growth.

The 2017 Equity Incentive Plan provided for the grant of a total of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates. As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.

2014 Equity Incentive Plan

On October 3, 2014, the stockholders approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan, or the Amended 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and Restated 2014 Equity Incentive Plan.

The Amended and Restated 2014 Plan, as amended provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan, as amended provides that the number of shares reserved and available for issuance will automatically increase each January 1, by four percent of the Company’s common stock on the immediately preceding December 31, adjusted for the number of shares of the Company’s common stock issuable upon conversion of any security that the Company may issue that is convertible into or exchangeable for the Company’s common stock, or such lesser number of shares as determined by the Company’s Board of Directors.

On January 1, 2022, pursuant to the Amended and Restated 2014 Plan, as amended annual evergreen feature, the number of shares authorized under the Amended and Restated 2014 Plan, as amended was increased by 840,181 shares to 1,238,785 shares. As of March 31, 2022, 474,720 shares remain available to be issued under the Amended and Restated 2014 Plan, as amended.

Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if there is a change in control as defined in the plan.

2014 Employee Stock Purchase Plan

On October 3, 2014, the stockholders approved the 2014 Employee Stock Purchase Plan, or the 2014 ESPP. The 2014 ESPP initially authorized the issuance of up to 3,513 shares of the Company’s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company’s Board of Directors prior to each such January 1st.

On January 1, 2022, pursuant to the increase per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 32,062 shares. As of March 31, 2022, the authorized number of shares under the 2014 ESPP is 32,062 and the number of shares available for issuance is 32,062. During the three months ended March 31, 2022 and 2021, no shares were issued under the 2014 ESPP.

Restricted Stock Units

The following table summarizes restricted stock unit, or RSU, activities for the three months ended March 31, 2022:

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2021		96,201		$	28.87
Granted		139,800			6.84
Forfeited		(6,100	)		6.90
Vested		(30,163	)		30.00
Non-vested as of March 31, 2022		199,738		$	13.95

The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the respective awards. As of March 31, 2022, the unamortized value of RSUs was $2,435. As of March 31, 2022, the weighted average remaining amortization period was 2.64 years. As of March 31, 2022 and December 31, 2021, 289,500 and 286,918 RSUs, respectively, have vested that have not yet been settled into shares of the Company’s common stock.

During the three months ended March 31, 2022, the Company issued 16,196 shares of the Company’s common stock from the net settlement of 27,581 RSUs. The Company paid $72 in connection with the net share settlement of these RSUs.

Stock Options

The following table summarizes stock option activities for the three months ended March 31, 2022:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (1)
Outstanding as of December 31, 2021		1,356,639		$	20.51		8.59	$	1
Granted		674,600			6.82		-		-
Exercised		-			-		-		-
Forfeited		(38,684	)		11.87		-		-
Expired		(12,500	)		15.30		-		-
Outstanding as of March 31, 2022		1,980,055		$	16.05		8.83	$	-

Exercisable as of March 31, 2022		593,192		$	21.29		8.01	$	-

(1)

Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the Company’s common stock on March 31, 2022. The intrinsic value of options exercised during the three months ended March 31, 2022 and 2021 was $0, respectively, as no options were exercised.

The weighted average grant date fair value per share of the options granted during the three months ended March 31, 2022 and 2021 was $5.37 and $15.20, respectively. As of March 31, 2022, there was approximately $14,369 of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of 3.03 years. The total unrecognized stock-based compensation cost will be adjusted for actual forfeitures as they occur.

Summary of Stock-Based Compensation Expense

The following tables summarize total stock-based compensation costs recognized:

	Three Months Ended March 31,
	2022		2021
Restricted stock units	$	314	$	1,303
Stock options		1,565		1,437
Total	$	1,879	$	2,740

Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as:

	Three Months Ended March 31,
	2022		2021
Research and development	$	366	$	270
General and administrative		1,513		2,470
Total	$	1,879	$	2,740

Net Loss Per Common Share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Common Share

11.

Net Loss per Common Share

The following table sets forth the computation of the net loss per share attributable to common stockholders, basic and diluted:

	As of March 31,
	2022			2021
Numerator:
Net loss attributable to common stockholders	$	10,755		$	13,465
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	$	11,250,127		$	11,226,929
Net loss per share attributable to common stockholders, basic and diluted	$	(0.96	)	$	(1.20	)

Since the Company was in a net loss position for all periods presented, net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	As of March 31,
	2022		2021
Stock options issued and outstanding		1,980,055		1,151,327
Restricted stock units issued and outstanding		489,238		379,744
Conversion of Series 1 Convertible Preferred Stock		8,029,039		8,029,039
Total potentially dilutive shares		10,498,332		9,560,110

Accounting Policies, by Policy (Policies)	3 Months Ended
Accounting Policies, by Policy (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	*Basis of Presentation* The accompanying condensed consolidated financial statements and the related disclosures as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2021 and 2020 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2021 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three months ended March 31, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Use of Estimates	*Use of Estimates* The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Significant items subject to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and contingencies. On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.
Concentrations of Credit Risk	*Concentrations of Credit Risk* Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash, cash equivalents and investments in marketable debt securities. The Company currently invests its excess cash primarily in money market funds and high quality investment grade marketable debt securities of corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.
Recent Accounting Pronouncements Not Yet Adopted	*Recent Accounting Pronouncements Not Yet Adopted* In June 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
Subsequent Events	*Subsequent Events* The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of financial instruments measured at fair value on a recurring basis

	March 31, 2022
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	14,718	$	-	$	-	$	14,718
Restricted cash, non-current:
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		93,044		-		93,044
Total	$	15,463	$	93,044	$	-	$	108,507

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	26,323	$	-	$	-	$	26,323
Restricted cash, non-current:
Money market funds		745		-		-		745
Marketable debt securities
Corporate bonds		-		94,972		-		94,972
Total	$	27,068	$	94,972	$	-	$	122,040

Marketable Debt Securities (Tables)

3 Months Ended

Mar. 31, 2022

Marketable Debt Securities [Abstract]

Schedule of marketable debt securities

	March 31, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate bonds - presented in marketable debt securities	$	62,535	$	-	$	(380	)	$	62,155
Corporate bonds - presented in marketable debt securities, non-current		31,451		-		(562	)		30,889
Total	$	93,986	$	-	$	(942	)	$	93,044

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Corporate Bonds - presented in marketable debt securities	$	55,548	$	-	$	(43	)	$	55,505
Corporate Bonds - presented in marketable debt securities, non-current		39,635		-		(168	)		39,467
Total	$	95,183	$	-	$	(211	)	$	94,972

Schedule of investment income

	March 31,
	2022			2021
Interest income	$	529		$	397
Accretion/(amortization) of discount/premium, net		(410	)		(282	)
Total interest and investment income	$	119		$	115

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2022

Prepaid Expenses and Other Current Assets [Abstract]

Schedule of prepaid expenses and other current assets

	As of
	March 31, 2022		December 31, 2021
Prepaid insurance	$	1,683	$	279
Prepaid research and development		463		684
Prepaid software		133		79
Accrued interest on marketable debt securities		528		634
Other prepaid expenses		287		173
Other current assets		4		34
Total	$	3,098	$	1,883

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

Schedule of accrued expenses

	As of
	March 31, 2022		December 31, 2021
Payroll	$	465	$	1,801
Taxes		52		41
Legal fees		56		29
Research and development costs		798		437
Other expenses		79		181
Total	$	1,450	$	2,489

Leases (Tables)

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Schedule of lease cost

	Three Months Ended March 31,
Lease cost	2022		2021
Operating lease cost	$	341	$	55
Short-term lease cost		3		61
Total	$	344	$	116

Schedule of other information related to leases

	As of March 31, 2022

Weighted-average discount rate		7.0	%
Weighted-average remaining lease term – operating lease (in months)		76

Schedule of annual minimum lease payments of operating lease liabilities

For Years Ending December 31,	Operating Lease Payments
2022 (excluding the three months ended March 31, 2022)	$	995
2023		1,327
2024		1,327
2025		1,395
2026		1,429
Thereafter		2,234
Total operating lease payments		8,707
Less: imputed interest		1,677
Present value of future minimum lease payments	$	7,030

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of restricted stock unit activities

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2021		96,201		$	28.87
Granted		139,800			6.84
Forfeited		(6,100	)		6.90
Vested		(30,163	)		30.00
Non-vested as of March 31, 2022		199,738		$	13.95

Schedule of stock option activities

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (1)
Outstanding as of December 31, 2021		1,356,639		$	20.51		8.59	$	1
Granted		674,600			6.82		-		-
Exercised		-			-		-		-
Forfeited		(38,684	)		11.87		-		-
Expired		(12,500	)		15.30		-		-
Outstanding as of March 31, 2022		1,980,055		$	16.05		8.83	$	-

Exercisable as of March 31, 2022		593,192		$	21.29		8.01	$	-

(1)

Schedule of total stock-based compensation costs

	Three Months Ended March 31,
	2022		2021
Restricted stock units	$	314	$	1,303
Stock options		1,565		1,437
Total	$	1,879	$	2,740

Schedule of stock-based compensation expense

	Three Months Ended March 31,
	2022		2021
Research and development	$	366	$	270
General and administrative		1,513		2,470
Total	$	1,879	$	2,740

Net Loss Per Common Share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Schedule of net loss per share attributable to common stockholders, basic and diluted

	As of March 31,
	2022			2021
Numerator:
Net loss attributable to common stockholders	$	10,755		$	13,465
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	$	11,250,127		$	11,226,929
Net loss per share attributable to common stockholders, basic and diluted	$	(0.96	)	$	(1.20	)

Schedule of weighted average dilutive common shares

	As of March 31,
	2022		2021
Stock options issued and outstanding		1,980,055		1,151,327
Restricted stock units issued and outstanding		489,238		379,744
Conversion of Series 1 Convertible Preferred Stock		8,029,039		8,029,039
Total potentially dilutive shares		10,498,332		9,560,110

Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash equivalents:
Money market funds	$ 14,718	$ 26,323
Restricted cash, non-current:
Money market funds	745	745
Marketable debt securities
Corporate bonds	93,044	94,972
Total	108,507	122,040
Level 1 [Member]
Cash equivalents:
Money market funds	14,718	26,323
Restricted cash, non-current:
Money market funds	745	745
Marketable debt securities
Corporate bonds
Total	15,463	27,068
Level 2 [Member]
Cash equivalents:
Money market funds
Restricted cash, non-current:
Money market funds
Marketable debt securities
Corporate bonds	93,044	94,972
Total	93,044	94,972
Level 3 [Member]
Cash equivalents:
Money market funds
Restricted cash, non-current:
Money market funds
Marketable debt securities
Corporate bonds
Total

Marketable Debt Securities (Details)	3 Months Ended
Marketable Debt Securities (Details)	Mar. 31, 2022 USD ($)
Marketable Debt Securities [Abstract]
Unrealized loss related to these securities	$ 133

Marketable Debt Securities (Details) - Schedule of marketable debt securities - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Amortized Cost	$ 93,986	$ 95,183
Unrealized Gains
Unrealized Losses	(942)	(211)
Estimated Fair Value	93,044	94,972
Corporate bonds - presented in marketable debt securities [Member]
Marketable Securities [Line Items]
Amortized Cost	62,535	55,548
Unrealized Gains
Unrealized Losses	(380)	(43)
Estimated Fair Value	62,155	55,505
Corporate bonds - presented in marketable debt securities, non-current [Member]
Marketable Securities [Line Items]
Amortized Cost	31,451	39,635
Unrealized Gains
Unrealized Losses	(562)	(168)
Estimated Fair Value	$ 30,889	$ 39,467

Marketable Debt Securities (Details) - Schedule of investment income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of investment income [Abstract]
Interest income	$ 529	$ 397
Accretion/(amortization) of discount/premium, net	(410)	(282)
Total interest and investment income	$ 119	$ 115

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 1,683	$ 279
Prepaid research and development	463	684
Prepaid software	133	79
Accrued interest on marketable debt securities	528	634
Other prepaid expenses	287	173
Other current assets	4	34
Total	$ 3,098	$ 1,883

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of accrued expenses [Abstract]
Payroll	$ 465	$ 1,801
Taxes	52	41
Legal fees	56	29
Research and development costs	798	437
Other expenses	79	181
Total	$ 1,450	$ 2,489

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating leases	$ 332	$ 52

Leases (Details) - Schedule of lease cost - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of lease cost [Abstract]
Operating lease cost	$ 341	$ 55
Short-term lease cost	3	61
Total	$ 344	$ 116

Leases (Details) - Schedule of other information related to leases	Mar. 31, 2022
Schedule of other information related to leases [Abstract]
Weighted-average discount rate	7.00%
Weighted-average remaining lease term – operating lease (in months)	76 months

Leases (Details) - Schedule of annual minimum lease payments of operating lease liabilities $ in Thousands	Dec. 31, 2021 USD ($)
Schedule of annual minimum lease payments of operating lease liabilities [Abstract]
2022	$ 995
2023	1,327
2024	1,327
2025	1,395
2026	1,429
Thereafter	2,234
Total operating lease payments	8,707
Less: imputed interest	1,677
Present value of future minimum lease payments	$ 7,030

Stockholders’ Equity (Details) - $ / shares	3 Months Ended
Stockholders’ Equity (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Stockholders’ Equity (Details) [Line Items]
Common stock authorized	100,000,000	100,000,000
Common shares of par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock shares issued	11,251,927	11,235,731
Common stock, shares outstanding	11,251,927	11,235,731
Voting description	The holders of the Company’s common stock are entitled to one vote per share.
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred shares of par value (in Dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock		8,028
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock authorized	100,000,000	100,000,000
Common shares of par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock shares issued	11,251,927	11,235,731
Common stock, shares outstanding	11,251,927	11,235,731
Series 1 Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred shares of par value (in Dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock	8,028
Preferred stock, shares issued	8,027	8,027
Preferred stock, shares outstanding	8,027	8,027
Conversion of stock shares	1,000
Conversion price per share (in Dollars per share)	$ 7.01

Stock-Based Compensation (Details) - USD ($)			3 Months Ended		12 Months Ended
Stock-Based Compensation (Details) - USD ($)	Mar. 26, 2020	Oct. 03, 2014	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jan. 01, 2022	Aug. 10, 2017
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized			100,000,000		100,000,000
Common stock shares issued			11,251,927		11,235,731
2020 Inducement Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Issuance of common stock	600,000
Shares available for issuance			438,834
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance							2,000,000
Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Employee stock purchase plan description		The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company’s Board of Directors prior to each such January 1st.
Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Remaining shares issued			474,720
2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance				32,062
Common stock, shares authorized		3,513
Number of shares authorized			32,062
Minimum [Member] \| Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized						840,181
Minimum [Member] \| 2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased						7,025
Maximum [Member] \| Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares authorized						1,238,785
Maximum [Member] \| 2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased						32,062
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Unamortized value of RSUs (in Dollars)			$ 2,435,000
Weighted average remaining amortization period			2 years 7 months 20 days
Number of RSUs			289,500		286,918
Common stock shares issued			16,196
Net settlement (in Dollars)			$ 27,581
Net share settlement (in Dollars)			$ 72
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Weighted average grant date fair value per share (in Dollars per share)			$ 5.37	$ 15.2
Unrecognized share based compensation for unvested stock option grants			14,369
Recognized over a weighted average period			3 years 10 days

Stock-Based Compensation (Details) - Schedule of restricted stock unit activities	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Stock-Based Compensation (Details) - Schedule of restricted stock unit activities [Line Items]
Non-vested Restricted Stock Units, Balance at ending	$ 199,738
Non-vested Weighted Average Grant Date Fair Value, Balance at ending	$ 13.95
Restricted Stock Unit [Member]
Stock-Based Compensation (Details) - Schedule of restricted stock unit activities [Line Items]
Non-vested Restricted Stock Units, Balance at beginning (in Shares) \| shares	96,201
Non-vested Weighted Average Grant Date Fair Value, Balance at beginning	$ 28.87
Granted ,Restricted Stock Units (in Shares) \| shares	139,800
Granted ,Weighted Average Grant Date Fair Value	$ 6.84
Forfeited ,Restricted Stock Units (in Shares) \| shares	(6,100)
Forfeited ,Weighted Average Grant Date Fair Value	$ 6.9
Vested, Restricted Stock Units (in Shares) \| shares	(30,163)
Vested ,Weighted Average Grant Date Fair Value	$ 30

Stock-Based Compensation (Details) - Schedule of stock option activities - Equity Option [Member]
$ / shares in Units, $ in Thousands

3 Months Ended

Mar. 31, 2022

USD ($)

$ / shares

Stock-Based Compensation (Details) - Schedule of stock option activities [Line Items]

Number of Options, Outstanding Beginning balance | shares

1,356,639

Weighted Average Exercise Price, Outstanding Beginning balance | $ / shares

$ 20.51

Weighted Average Remaining Contractual Term (years), Outstanding Beginning balance

8 years 7 months 2 days

Aggregate Intrinsic Value, Outstanding Beginning balance | $

$ 1

^[1]

Number of Options, Outstanding Ending balance | shares

1,980,055

Weighted Average Exercise Price, Outstanding Ending balance | $ / shares

$ 16.05

Weighted Average Remaining Contractual Term (years), Outstanding Ending balance

8 years 9 months 29 days

Aggregate Intrinsic Value, Outstanding Ending balance | $

^[1]

Number of Options, Exercisable | shares

593,192

Weighted Average Exercise Price, Exercisable | $ / shares

$ 21.29

Weighted Average Remaining Contractual Term (years), Exercisable

8 years 3 days

Aggregate Intrinsic Value, Exercisable | $

^[1]

Number of Options, Granted | shares

674,600

Weighted Average Exercise Price, Granted | $ / shares

$ 6.82

Weighted Average Remaining Contractual Term (years), Granted

Aggregate Intrinsic Value, Granted | $

^[1]

Number of Options, Exercised | shares

Weighted Average Exercise Price, Exercised | $ / shares

Weighted Average Remaining Contractual Term (years), Exercised

Aggregate Intrinsic Value, Exercised | $

^[1]

Number of Options, Forfeited | shares

(38,684)

Weighted Average Exercise Price, Forfeited | $ / shares

$ 11.87

Weighted Average Remaining Contractual Term (years), Forfeited

Aggregate Intrinsic Value, Forfeited | $

^[1]

Number of Options, Expired | shares

(12,500)

Weighted Average Exercise Price, Expired | $ / shares

$ 15.3

Weighted Average Remaining Contractual Term (years),Expired

Aggregate Intrinsic Value, Expired | $

^[1]

[1]

Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]
Restricted stock units	$ 314	$ 1,303
Total stock-based compensation	1,879	2,740
Stock options [Member]
Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]
Total stock-based compensation	$ 1,565	$ 1,437

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,879	$ 2,740
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	366	270
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,513	$ 2,470

Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to common stockholders	$ 10,755	$ 13,465
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	11,250,127	11,226,929
Net loss per share attributable to common stockholders, basic and diluted	$ (0.96)	$ (1.2)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of weighted average dilutive common shares [Abstract]
Stock options issued and outstanding	1,980,055	1,151,327
Restricted stock units issued and outstanding	489,238	379,744
Conversion of Series 1 Convertible Preferred Stock	8,029,039	8,029,039
Total potentially dilutive shares	10,498,332	9,560,110